Received Jun 27, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAPIPV | DTAP + IPV (KINRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | Y49BZ | — |
Patient received a dose of Kinrix out of the recommended age.; This non-serious case was reported by a nurse via call center representative and described the occurrence of inappropriate age at vaccine administration in a 3-year-old female patient who received DTPa-IPV (Kinrix) (batch number Y49BZ, expiry date 17-MAY-2026) for prophylaxis. On 21-JAN-2025, the patient received Kinrix. On 21-JAN-2025, an unknown time after receiving Kinrix, the patient experienced inappropriate age at vaccine administration (Verbatim: Patient received a dose of Kinrix out of the recommended age.). The outcome of the inappropriate age at vaccine administration was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 18-JUN-2025 The nurse reported that they administered a dose of Kinrix to 6 different patients under the age of 4 years old, which led to inappropriate age at vaccine administration. The reporter said that did they need to continue with the same schedule as recommended in the package insert. This was 1 of 6 linked cases, reported by the same reporter.; Sender's Comments: GSK-US2025076584:Same reporter/Diffrent patient US-GSK-US2025076588:Same reporter/Diffrent patient US-GSK-US2025076587:Same reporter/Diffrent patient